DK1076566T3 - Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet - Google Patents

Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet

Info

Publication number
DK1076566T3
DK1076566T3 DK99919755T DK99919755T DK1076566T3 DK 1076566 T3 DK1076566 T3 DK 1076566T3 DK 99919755 T DK99919755 T DK 99919755T DK 99919755 T DK99919755 T DK 99919755T DK 1076566 T3 DK1076566 T3 DK 1076566T3
Authority
DK
Denmark
Prior art keywords
antigen
express
constructively
attenuated salmonella
salmonella mutants
Prior art date
Application number
DK99919755T
Other languages
Danish (da)
English (en)
Inventor
Marcelo Sztein
Myron M Levine
Fernando R Noriega
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of DK1076566T3 publication Critical patent/DK1076566T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/879—Salmonella

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99919755T 1998-05-13 1999-04-30 Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet DK1076566T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/076,761 US6190669B1 (en) 1998-05-13 1998-05-13 Attenuated mutants of salmonella which constitutively express the Vi antigen

Publications (1)

Publication Number Publication Date
DK1076566T3 true DK1076566T3 (da) 2006-11-13

Family

ID=22134022

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99919755T DK1076566T3 (da) 1998-05-13 1999-04-30 Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet

Country Status (16)

Country Link
US (1) US6190669B1 (xx)
EP (1) EP1076566B1 (xx)
JP (1) JP4363782B2 (xx)
AT (1) ATE333285T1 (xx)
AU (1) AU754795B2 (xx)
CA (1) CA2328056C (xx)
DE (1) DE69932425T2 (xx)
DK (1) DK1076566T3 (xx)
ES (1) ES2268864T3 (xx)
HU (1) HUP0101747A3 (xx)
MX (1) MXPA00011075A (xx)
NO (1) NO20005672L (xx)
NZ (1) NZ508110A (xx)
PL (1) PL192378B1 (xx)
WO (1) WO1999058146A1 (xx)
ZA (1) ZA200006381B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2127829T3 (es) * 1992-07-31 1999-05-01 Medeva Holdings Bv Expresion de proteinas recombinantes fusionadas en bacterias atenuadas.
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
JP2002531135A (ja) * 1998-12-04 2002-09-24 ユニヴァーシティ オブ マニトーバ クラミジア感染に対する２段階免疫感作法
US7026155B2 (en) * 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
ATE269104T1 (de) * 1999-12-28 2004-07-15 Akzo Nobel Nv Salmonella impfstoff, der keinen antikörper gegen flagellin oder gegen flagella induziert
AU5554301A (en) * 2000-04-20 2001-11-07 Univ Maryland Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US7541043B2 (en) 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
AU2003250250B2 (en) * 2002-06-19 2008-02-14 Intrexon Actobiotics Nv Methods and means to promote gut absorption
EP1560935A2 (en) * 2002-11-15 2005-08-10 VIB vzw Self-containing lactobacillus strain
US8475810B2 (en) * 2005-10-28 2013-07-02 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi a and uses thereof
US8137930B2 (en) 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
WO2007062371A2 (en) * 2005-11-23 2007-05-31 University Of Maryland, Baltimore Live vector vaccine and uses thereof
US8748126B2 (en) 2005-11-29 2014-06-10 Actogenix N.V. Induction of mucosal tolerance to antigens
CA2643740A1 (en) * 2006-03-20 2007-10-11 Vrije Universiteit Brussel Live attenuated salmonella vaccine
EP2004802A1 (en) * 2006-03-20 2008-12-24 Vrije Universiteit Brussel Live attenuated salmonella vaccine
US8604178B2 (en) 2006-09-18 2013-12-10 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
CN101605559B (zh) 2007-01-25 2014-04-23 阿克图杰尼斯公司 使用遗传修饰的乳杆菌通过抗原的粘膜递送治疗免疫疾病
US20110020399A1 (en) * 2007-04-16 2011-01-27 University Of Maryland, Baltimore Vaccines and Immunomodulatory Therapies for Tularemia
CN102037135A (zh) * 2007-10-30 2011-04-27 阿肯色大学评议会 增强对有鞭毛的细菌的免疫反应的组合物和方法
DK2214701T3 (en) 2007-11-01 2016-12-12 Univ Arkansas CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
WO2010141143A2 (en) * 2009-04-21 2010-12-09 Vivocure, Inc. Engineered avirulent bacteria strains and use in medical treatments
DK2525817T3 (en) 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses
JP5746333B2 (ja) 2010-06-09 2015-07-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー カンピロバクター感染を減少させるワクチン及び方法
US9833503B2 (en) 2012-02-24 2017-12-05 President And Fellows Of Harvard College Methods for displaying polypeptides and uses thereof
PT2956165T (pt) 2013-02-14 2019-11-29 Texas A & M Univ Sys Composições e métodos de potenciação das respostas imunitárias frente a eimeria ou limitação de uma infeção por eimeria
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
EP3452069A4 (en) 2016-05-03 2020-02-12 The Board of Trustees of the University of Arkansas Yeast vaccine vector with immunostimulating and antigenic polypeptides and method for using them
KR20240054373A (ko) * 2021-09-10 2024-04-25 리젠츠 오브 더 유니버시티 오브 미네소타 종양의 비독성 콜로니화를 위해 조작된 살모넬라

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5783196A (en) 1996-04-09 1998-07-21 University Of Maryland At Baltimore Gua mutants of shigella spp. and vaccines containing the same

Also Published As

Publication number Publication date
DE69932425D1 (de) 2006-08-31
NO20005672L (no) 2001-01-15
EP1076566A4 (en) 2005-01-05
EP1076566B1 (en) 2006-07-19
HUP0101747A3 (en) 2002-03-28
ATE333285T1 (de) 2006-08-15
PL192378B1 (pl) 2006-10-31
US6190669B1 (en) 2001-02-20
ES2268864T3 (es) 2007-03-16
HUP0101747A2 (hu) 2001-09-28
JP2002514398A (ja) 2002-05-21
AU754795B2 (en) 2002-11-28
CA2328056C (en) 2010-07-06
NO20005672D0 (no) 2000-11-10
EP1076566A1 (en) 2001-02-21
MXPA00011075A (es) 2002-04-24
AU3740599A (en) 1999-11-29
DE69932425T2 (de) 2007-03-08
WO1999058146A1 (en) 1999-11-18
JP4363782B2 (ja) 2009-11-11
NZ508110A (en) 2002-10-25
PL344593A1 (en) 2001-11-05
ZA200006381B (en) 2002-02-07
CA2328056A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
DK1076566T3 (da) Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet
DK142391D0 (da) Indretning til tilberedning, servering og opbevaring af f.eks. madvarer
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
DE69841437D1 (de) Bakterielle impfstoffe, enthaltend auxotrophe attenuierte listerienstämme, welche heterologe antigene exprimieren
BR9916132A (pt) Composições e utilização das mesmas
FI913215A (fi) Additionspolymeriseringskatalysator, som aktiveras medelst oxidering.
DK1362597T3 (da) Antigene peptider, der er afledt af telomerase
GEP20105118B (en) Anti-vegf antibodies
MX9102664A (es) Composiciones termofijas de recubrimiento que tienen dureza mejorada.
TR199600128A2 (tr) Sekil verilebilir, isiya karsi stabilize edilebilir dokunmus bukleli mamuller.
DK1545597T3 (da) Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
MX9102850A (es) Composiciones polimericas que contienen halogeno, estabilizadas.
DE69103489D1 (de) Filmbildende Organopolysiloxanzusammensetzung.
IT9022356A0 (it) Indumento refrigerante, in particolare del tipo giubbotto o simile.
FR2661183B1 (fr) Compositions stabilisees de polymere halogene.
TR200401569T4 (tr) Flagelin ya da flagelle'ya karşı antikorların oluşumuna sebep olmayan salmonelle aşısı
DE69738512D1 (de) Epstein-barr virus type b ctl epitopen
DE69102205D1 (de) Oberflächenaktive Polyorganosiloxane.
FI912056A0 (fi) Kopplingsanordning, vilken omfattar efter varandra foeljande kopplingssektioner.
NO990849D0 (no) Substituerte 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyklohepta (b) benzofuraner
IT8123022A0 (it) Frigorifero, congelatore o simile, elettrodomestico, in particolare perfezionato.
FI911258A (fi) Foer kylmaskin, i synnerhet foer hushaollskylskaop avsedd plaotkondensator.
TR199600082A2 (tr) Gelistirilmis üstüne yazma özelliklerine sahip, ozona zarar vermeyen düzeltme yapma sivisi.